| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm |
| Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 4.35 mm | (no burn) | 2.41 mm |
| Cash used (since last report) | n/a | n/a | n/a | 103.55 mm | n/a | 57.24 mm |
| Cash remaining | n/a | n/a | n/a | 48.29 mm | n/a | 94.61 mm |
| Runway (months of cash) | n/a | n/a | n/a | 11.1 | n/a | 39.3 |
| 13F holders | Current |
|---|---|
| Total holders | 6 |
| Opened positions | 0 |
| Closed positions | 80 |
| Increased positions | 0 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 1.02 bn |
| Total shares | 13.34 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GILD Gilead Sciences | 5.54 mm | $55.73 mm |
| Cowen Financial Products | 3.65 mm | $4.05 mm |
| BMY Bristol-Myers Squibb | 3.46 mm | $17.25 mm |
| Opaleye Management | 669.94 k | $917.82 mm |
| California State Teachers Retirement System | 15.67 k | $28.98 mm |
| Tang Capital Partners | 10.00 k | $19.00 k |
